Sign In
Buy EOLS
$6.03
-0.140 (-2.27%)
At Close: Jun 03, 2026
Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates
01:25pm, Tuesday, 02'nd Aug 2022 Zacks Investment Research
Evolus, Inc. (EOLS) delivered earnings and revenue surprises of -58.33% and 0.90%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Is Deciphera Pharmaceuticals (DCPH) Outperforming Other Medical Stocks This Year?
01:40pm, Friday, 22'nd Jul 2022 Zacks Investment Research
Here is how Deciphera Pharmaceuticals, Inc. (DCPH) and Evolus, Inc. (EOLS) have performed compared to their sector so far this year.
Evolus to Report Second Quarter 2022 Results and Provide Business Update
08:45am, Tuesday, 19'th Jul 2022
NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus announces it will report its second quarter 2022 financial results and provide a business update on Tuesday, August 2, 2022, before market.
Does Evolus, Inc. (EOLS) Have the Potential to Rally 28% as Wall Street Analysts Expect?
01:55pm, Wednesday, 08'th Jun 2022 Zacks Investment Research
The mean of analysts' price targets for Evolus, Inc. (EOLS) points to a 28.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among ana
Is Computer Programs and Systems (CPSI) Stock Outpacing Its Medical Peers This Year?
01:40pm, Wednesday, 08'th Jun 2022 Zacks Investment Research
Here is how Computer Programs and Systems (CPSI) and Evolus, Inc. (EOLS) have performed compared to their sector so far this year.
Wall Street Analysts Predict a 34% Upside in Evolus, Inc. (EOLS): Here's What You Should Know
01:55pm, Monday, 23'rd May 2022 Zacks Investment Research
The average of price targets set by Wall Street analysts indicates a potential upside of 34.2% in Evolus, Inc. (EOLS). While the effectiveness of this highly sought-after metric is questionable, the p
Has Evolus (EOLS) Outpaced Other Medical Stocks This Year?
01:40pm, Monday, 23'rd May 2022 Zacks Investment Research
Here is how Evolus, Inc. (EOLS) and Computer Programs and Systems (CPSI) have performed compared to their sector so far this year.
Has Evolus (EOLS) Outpaced Other Medical Stocks This Year?
11:19am, Monday, 23'rd May 2022
Here is how Evolus, Inc. (EOLS) and Computer Programs and Systems (CPSI) have performed compared to their sector so far this year.
Benzinga's Top Ratings Upgrades, Downgrades For May 13, 2022
02:01pm, Friday, 13'th May 2022 Benzinga
Upgrades
B of A Securities upgraded the previous rating for Ritchie Bros Auctioneers Inc (NYSE:RBA) from Underperform to Neutral. In the first quarter, Ritchie Bros Auctioneers showed an EPS of $0.46,
Benzinga's Top Ratings Upgrades, Downgrades For May 12, 2022
02:04pm, Thursday, 12'th May 2022 Benzinga
Upgrades
For Warner Bros.Discovery Inc (NASDAQ:WBD), Cowen & Co. upgraded the previous rating of Market Perform to Outperform. The current stock performance of Warner Bros.Discovery shows a 52-week-h
Evolus to Participate in the H.C. Wainwright Global Investment Conference
08:45am, Wednesday, 11'th May 2022
NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus announces that members of its management team will be participating in the H.C. Wainwright Global Investment Conference.
Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates
10:15pm, Tuesday, 10'th May 2022 Zacks Investment Research
Evolus, Inc. (EOLS) delivered earnings and revenue surprises of 34.15% and 12.03%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Evolus, Inc. (EOLS) CEO David Moatazedi on Q1 2022 Results - Earnings Call Transcript
08:44pm, Tuesday, 10'th May 2022
Evolus, Inc. (NASDAQ:EOLS ) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants David Erickson - Vice President-Investor Relations David Moatazedi - President and Chief Execu
Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates
07:34pm, Tuesday, 10'th May 2022
Evolus, Inc. (EOLS) delivered earnings and revenue surprises of 34.15% and 12.03%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zynex Inc. (ZYXI) Q1 Earnings Miss Estimates
09:25pm, Thursday, 28'th Apr 2022 Zacks Investment Research
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of -40% and 0.66%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
